{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:06:49Z","timestamp":1793725609052,"version":"4.6.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T00:00:00Z","timestamp":1696032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T00:00:00Z","timestamp":1696032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972968"],"award-info":[{"award-number":["81972968"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82103776"],"award-info":[{"award-number":["82103776"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Three-Year Plan of Shanghai Municipal Health Commission","award":["GWV-10.2-YQ27"],"award-info":[{"award-number":["GWV-10.2-YQ27"]}]},{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","award":["No.20214Y0012"],"award-info":[{"award-number":["No.20214Y0012"]}],"id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Zhejiang Provincial Natural Science Foundation of Chinae","award":["LQ23H220001"],"award-info":[{"award-number":["LQ23H220001"]}],"id":[{"id":"https:\/\/ror.org\/04aqat463","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the Project of South Zhejiang Institute of Radiation Medicine and Nuclear Technology","award":["No.ZFY-2021-K-002"],"award-info":[{"award-number":["No.ZFY-2021-K-002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Our previous study first showed that ATR-binding long noncoding RNA (lncRNA) is necessary for ATR function and promotes cancer resistance. However, the specific lncRNAs instrumental in ATR activation remain largely unclear, which limits our comprehensive understanding of this critical biological process.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>RNA immunoprecipitation (RIP) followed by RNA sequencing was employed to identify ATR-binding lncRNAs, which were further validated using RIP-qPCR assays. Immunofluorescence staining and Western blotting were applied to detect the activation of DNA damage repair factors. After the effect of scaRNA2 on cellular sensitivity to DNA-damaging reagents was determined, the effects of scaRNA2 on radiotherapy were investigated in patient-derived organoids and xenograft preclinical models. The clinical relevance of scaRNA2 was also validated in tissues isolated from rectal cancer patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>ScaRNA2 was identified as the most enriched ATR-binding lncRNA and was found to be essential for homologous recombination (HR) mediated DNA damage repair. Furthermore, scaRNA2 knockdown abrogated the recruitment of ATR and its substrates in response to DNA damage. Mechanistically, scaRNA2 was observed to be necessary for Exo1-mediated DNA end resection and bridged the MRN complex to ATR activation. Knockdown of scaRNA2 effectively increased the sensitivity of cancer cells to multiple kinds of DNA damage-related chemoradiotherapy. Preclinically, knockdown of scaRNA2 improved the effects of radiotherapy on patient-derived organoids and xenograft models. Finally, an increase in scaRNA2 colocalized with ATR was also found in clinical patients who were resistant to radiotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ScaRNA2 was identified as the most abundant lncRNA bound to ATR and was demonstrated to bridge DNA end resection to ATR activation; thus, it could be applied as a potent target for combined cancer treatments with chemoradiotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-023-02829-4","type":"journal-article","created":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T22:01:46Z","timestamp":1696024906000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["ATR-binding lncRNA ScaRNA2 promotes cancer resistance through facilitating efficient DNA end resection during homologous recombination repair"],"prefix":"10.1186","volume":"42","author":[{"given":"Yuanyuan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijie","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhipeng","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengzhe","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,30]]},"reference":[{"key":"2829_CR1","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/s41580-019-0152-0","volume":"20","author":"R Scully","year":"2019","unstructured":"Scully R, Panday A, Elango R, Willis NA. DNA double-strand break repair-pathway choice in somatic mammalian cells. Nat Rev Mol Cell Biol. 2019;20:698\u2013714.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2829_CR2","doi-asserted-by":"publisher","first-page":"5653","DOI":"10.1016\/j.cell.2021.10.002","volume":"184","author":"JA Hussmann","year":"2021","unstructured":"Hussmann JA, et al. Mapping the genetic landscape of DNA double-strand break repair. Cell. 2021;184:5653\u201369. e5625.","journal-title":"Cell."},{"key":"2829_CR3","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41392-021-00648-7","volume":"6","author":"R Huang","year":"2021","unstructured":"Huang R, Zhou PK. DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy. Signal Transduct Target Ther. 2021;6:254.","journal-title":"Signal Transduct Target Ther"},{"key":"2829_CR4","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1038\/s41422-018-0086-7","volume":"28","author":"ST Sizemore","year":"2018","unstructured":"Sizemore ST, et al. Pyruvate kinase M2 regulates homologous recombination-mediated DNA double-strand break repair. Cell Res. 2018;28:1090\u2013102.","journal-title":"Cell Res"},{"key":"2829_CR5","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.1200\/JCO.19.02404","volume":"38","author":"TA Yap","year":"2020","unstructured":"Yap TA, et al. Phase I trial of first-in-class ATR inhibitor M6620 (VX-970) as monotherapy or in combination with carboplatin in patients with advanced solid tumors. J Clin Oncol. 2020;38:3195\u2013204.","journal-title":"J Clin Oncol"},{"key":"2829_CR6","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1158\/2159-8290.CD-20-0868","volume":"11","author":"TA Yap","year":"2021","unstructured":"Yap TA, et al. First-in-human trial of the oral ataxia telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in patients with advanced solid tumors. Cancer Discov. 2021;11:80\u201391.","journal-title":"Cancer Discov"},{"key":"2829_CR7","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1038\/ncb3645","volume":"19","author":"F Storici","year":"2017","unstructured":"Storici F, Tichon AE. RNA takes over control of DNA break repair. Nat Cell Biol. 2017;19:1382\u20134.","journal-title":"Nat Cell Biol"},{"key":"2829_CR8","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature11179","volume":"488","author":"S Francia","year":"2012","unstructured":"Francia S, et al. Site-specific DICER and DROSHA RNA products control the DNA-damage response. Nature. 2012;488:231\u20135.","journal-title":"Nature"},{"key":"2829_CR9","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1038\/ncb3643","volume":"19","author":"F Michelini","year":"2017","unstructured":"Michelini F, et al. Damage-induced lncRNAs control the DNA damage response through interaction with DDRNAs at individual double-strand breaks. Nat Cell Biol. 2017;19:1400\u201311.","journal-title":"Nat Cell Biol"},{"key":"2829_CR10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41419-020-03302-2","volume":"12","author":"Z Guo","year":"2021","unstructured":"Guo Z, et al. LncRNA linc00312 suppresses radiotherapy resistance by targeting DNA-PKcs and impairing DNA damage repair in nasopharyngeal carcinoma. Cell Death Dis. 2021;12:69.","journal-title":"Cell Death Dis"},{"key":"2829_CR11","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.15252\/embr.201540437","volume":"16","author":"V Sharma","year":"2015","unstructured":"Sharma V, et al. A BRCA1-interacting lncRNA regulates homologous recombination. EMBO Rep. 2015;16:1520\u201334.","journal-title":"EMBO Rep"},{"key":"2829_CR12","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1038\/s41418-020-0581-5","volume":"27","author":"D Wang","year":"2020","unstructured":"Wang D, et al. LRIK interacts with the Ku70-Ku80 heterodimer enhancing the efficiency of NHEJ repair. Cell Death Differ. 2020;27:3337\u201353.","journal-title":"Cell Death Differ"},{"key":"2829_CR13","doi-asserted-by":"publisher","first-page":"e3000666","DOI":"10.1371\/journal.pbio.3000666","volume":"18","author":"K Zhao","year":"2020","unstructured":"Zhao K, Wang X, Xue X, Li L, Hu Y. A long noncoding RNA sensitizes genotoxic treatment by attenuating ATM activation and homologous recombination repair in cancers. PLoS Biol. 2020;18:e3000666.","journal-title":"PLoS Biol"},{"key":"2829_CR14","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1093\/nar\/gkp988","volume":"38","author":"MA Gerard","year":"2010","unstructured":"Gerard MA, et al. The scaRNA2 is produced by an independent transcription unit and its processing is directed by the encoding region. Nucleic Acids Res. 2010;38:370\u201381.","journal-title":"Nucleic Acids Res"},{"key":"2829_CR15","doi-asserted-by":"publisher","first-page":"6673","DOI":"10.1073\/pnas.102167799","volume":"99","author":"K Unsal-Kacmaz","year":"2002","unstructured":"Unsal-Kacmaz K, Makhov AM, Griffith JD, Sancar A. Preferential binding of ATR protein to UV-damaged DNA. Proc Natl Acad Sci U S A. 2002;99:6673\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2829_CR16","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nature24023","volume":"549","author":"N Arnoult","year":"2017","unstructured":"Arnoult N, et al. Regulation of DNA repair pathway choice in S and G2 phases by the NHEJ inhibitor CYREN. Nature. 2017;549:548\u201352.","journal-title":"Nature"},{"key":"2829_CR17","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12943-021-01382-y","volume":"20","author":"L Liu","year":"2021","unstructured":"Liu L, et al. Long non-coding RNA ANRIL promotes homologous recombination-mediated DNA repair by maintaining ATR protein stability to enhance cancer resistance. Mol Cancer. 2021;20:94.","journal-title":"Mol Cancer"},{"key":"2829_CR18","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1016\/j.celrep.2017.08.008","volume":"20","author":"W Daddacha","year":"2017","unstructured":"Daddacha W, et al. SAMHD1 promotes DNA End resection to facilitate DNA repair by homologous recombination. Cell Rep. 2017;20:1921\u201335.","journal-title":"Cell Rep"},{"key":"2829_CR19","doi-asserted-by":"publisher","first-page":"9325","DOI":"10.1093\/nar\/gkt672","volume":"41","author":"X Chen","year":"2013","unstructured":"Chen X, Paudyal SC, Chin RI, You Z. PCNA promotes processive DNA end resection by Exo1. Nucleic Acids Res. 2013;41:9325\u201338.","journal-title":"Nucleic Acids Res"},{"key":"2829_CR20","doi-asserted-by":"publisher","first-page":"10016","DOI":"10.1128\/MCB.24.22.10016-10025.2004","volume":"24","author":"D Nakada","year":"2004","unstructured":"Nakada D, Hirano Y, Sugimoto K. Requirement of the Mre11 complex and exonuclease 1 for activation of the Mec1 signaling pathway. Mol Cell Biol. 2004;24:10016\u201325.","journal-title":"Mol Cell Biol"},{"key":"2829_CR21","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S1470-2045(11)70097-3","volume":"12","author":"W van Gijn","year":"2011","unstructured":"van Gijn W, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12:575\u201382.","journal-title":"Lancet Oncol"},{"key":"2829_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1146\/annurev.biochem.73.011303.073723","volume":"73","author":"A Sancar","year":"2004","unstructured":"Sancar A, Lindsey-Boltz LA, Unsal-Ka\u00e7maz K, Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem. 2004;73:39\u201385.","journal-title":"Annu Rev Biochem"},{"key":"2829_CR23","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.tibs.2020.07.001","volume":"45","author":"CJ Guo","year":"2020","unstructured":"Guo CJ, Xu G, Chen LL. Mechanisms of long noncoding RNA nuclear retention. Trends Biochem Sci. 2020;45:947\u201360.","journal-title":"Trends Biochem Sci"},{"key":"2829_CR24","doi-asserted-by":"publisher","first-page":"10157","DOI":"10.1002\/jcp.27684","volume":"234","author":"PF Zhang","year":"2019","unstructured":"Zhang PF, et al. The lncRNA SCARNA2 mediates colorectal cancer chemoresistance through a conserved microRNA-342-3p target sequence. J Cell Physiol. 2019;234:10157\u201365.","journal-title":"J Cell Physiol"},{"key":"2829_CR25","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1038\/s41467-022-28646-5","volume":"13","author":"S Bergstrand","year":"2022","unstructured":"Bergstrand S, et al. Small Cajal body-associated RNA 2 (scaRNA2) regulates DNA repair pathway choice by inhibiting DNA-PK. Nat Commun. 2022;13:1015.","journal-title":"Nat Commun"},{"key":"2829_CR26","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/nrm2450","volume":"9","author":"KA Cimprich","year":"2008","unstructured":"Cimprich KA, Cortez D. ATR: an essential regulator of genome integrity. Nat Rev Mol Cell Biol. 2008;9:616\u201327.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2829_CR27","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1038\/ncb3422","volume":"18","author":"P Haahr","year":"2016","unstructured":"Haahr P, et al. Activation of the ATR kinase by the RPA-binding protein ETAA1. Nat Cell Biol. 2016;18:1196\u2013207.","journal-title":"Nat Cell Biol"},{"key":"2829_CR28","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1038\/s12276-020-00519-1","volume":"52","author":"F Zhao","year":"2020","unstructured":"Zhao F, Kim W, Kloeber JA, Lou Z. DNA end resection and its role in DNA replication and DSB repair choice in mammalian cells. Exp Mol Med. 2020;52:1705\u201314.","journal-title":"Exp Mol Med"},{"key":"2829_CR29","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.gpb.2016.05.002","volume":"14","author":"T Liu","year":"2016","unstructured":"Liu T, Huang J. DNA end resection: facts and mechanisms. Genomics Proteomics Bioinformatics. 2016;14:126\u201330.","journal-title":"Genomics Proteomics Bioinformatics"},{"key":"2829_CR30","doi-asserted-by":"publisher","first-page":"e1002801","DOI":"10.1371\/journal.pgen.1002801","volume":"8","author":"SJ Lin","year":"2012","unstructured":"Lin SJ, et al. The Rad4(TopBP1) ATR-activation domain functions in G1\/S phase in a chromatin-dependent manner. PLoS Genet. 2012;8:e1002801.","journal-title":"PLoS Genet"},{"key":"2829_CR31","doi-asserted-by":"publisher","first-page":"e104036","DOI":"10.15252\/embj.2019104036","volume":"39","author":"X Feng","year":"2020","unstructured":"Feng X, et al. ATR inhibition potentiates ionizing radiation-induced interferon response via cytosolic nucleic acid-sensing pathways. EMBO J. 2020;39:e104036.","journal-title":"EMBO J"},{"key":"2829_CR32","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/1535-7163.MCT-19-0019","volume":"19","author":"AM Wengner","year":"2020","unstructured":"Wengner AM, et al. The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage-inducing or repair-compromising therapies in preclinical cancer models. Mol Cancer Ther. 2020;19:26\u201338.","journal-title":"Mol Cancer Ther"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-023-02829-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-023-02829-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-023-02829-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T15:08:21Z","timestamp":1700492901000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-023-02829-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,30]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2829"],"URL":"https:\/\/doi.org\/10.1186\/s13046-023-02829-4","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,30]]},"assertion":[{"value":"12 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The whole study design and protocols were approved by the Ethics Committee of Naval Medical University, China, in accordance with the instructions for the Care and Use of Laboratory Animals published by the US NIH (Publication No. 96\u201301).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have agreed to publish this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"256"}}